Reversible agranulocytosis associated with oral terbinafine for onychomycosis.
Ornstein
D L
DL
Section of Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, NH 03756, USA.
Ely
P
P
D000284:Administration, Oral; D000380:Agranulocytosis / Q000139:chemically induced*; D000935:Antifungal Agents / Q000009:adverse effects*; D005260:Female; D005533:Foot Dermatoses / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects*; D014009:Onychomycosis / Q000188:drug therapy*; D000077291:Terbinafine
D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine